The fact that the GLD has performed at par with the broader equity market is a major red flag for equities. Read more to see ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Read here for a discussion on semiconductor industry uncertainties from US-China trade tensions, AI competition, and ...

Innoviz Technologies faces financial challenges and lack of profitability in the competitive automotive industry. Read why I ...

The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...

AI capex is ramping up among major hyperscalers as they significantly increase their investments. Read what this means for ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

Global X AIQ ETF is a top buy with strong performance and diverse holdings, outperforming peers LRNZ and THNQ. Click here to ...

Lindt & Sprüngli remains resilient amid rising cocoa prices, with organic revenue up 7.8% in FY 2024. Find out what justifies ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...